The Neurobiology of Parkinson's Disease Essay

Parkinson’s disease is a very well-known disease. It plagues about five million people worldwide, about a million of those cases are in the United States. A person does not lower their chances of getting Parkinson’s by living in a certain part of the world. It is not more, likely to happen in one location than, another. It has to do with age and genetics (“Demographics of parkinson’s,” 2014). It is a disease of the older generation, around about one percent of people over the age of 60 years old have Parkinson’s disease (Hauser, 2014). As one ages the likelihood of a person developing goes up. About four percent of people over the age of 80 years old develop Parkinson’s disease. The percentage of people who have Parkinson’s that are younger than 40 years old, is less than 10 percent. It is more

Many may not know Parkinson’s disease is the second most common neurodegenerative disorder in the world. This disease is most seen in the elderly starting at 62 years of age although, younger individuals can still have the disease it isn’t common. Parkinson’s make it difficult for its victims to carry out everyday activities that might have once been easy for them. As the disease progresses it makes it hard for the patient to do things like walk, stand, swallow and speak. A great deal of people don’t realize how helpful therapy can be when dealing with such disease!

Parkinson disease (PD), also referred to as Parkinson’s disease and paralysis agitans, is a progressive neurodegenerative disease that is the third most common neurologic disorder of older adults. It is a debilitating disease affecting motor ability and is characterized by four cardinal symptoms: tremor rigidity, bradykinesia or kinesis (slow movement/no movement), and postural instability. Most people have primary, or idiopathic, disease. A few patients have secondary parkinsonian symptoms from conditions such as brain tumors and certain anti-psychotic drugs.

Parkinson’s disease, a type of dementia also known as idiopathic or primary parkinsonism, paralysis agitans, or hypokinetic rigid syndrome/HRS, is on the rise in the U.S. Each year there are over 60,000 new cases in the U.S. alone. With the average person diagnosed with Parkinson’s disease over the age of 65 and America’s rapidly growing elderly population, awareness and concern are becoming significant points of interest for many healthcare professionals.

Parkinson's Disease is a literally crippling neurodegenerative disorder, manifested in about 1% of the aged population. People who have Parkinson's Disease gradually lose control of their movements; specific symptoms include, "tremor, slowness of movement, stiffness, difficulty in walking, and loss of balance." (1) Evidence strongly suggests that Parkinson's Disease is the result of severe cell loss in the substantia nigra. This brain structure is principally involved in the production of dopamine. (2) Dopamine, among other functions, is the neurotransmitter involved in initiation of movement. Hence, the link between dopaminergic cell loss and cessation of voluntary movement, as manifested

The symptoms of Parkinson's disease that Ali experienced began in the early 1980's. His feet didn't seem to move as fast as they once did, and the usually proud man slouched forward in a defeated position. His thinking was also beginning to be impaired.

Parkinson’s Disease is a long-term progressive neurodegenerative disease consisting of motor system impairment, neuropsychiatric, and nonmotor features. The disease is characterized by the following key clinical features: bradykinesia, resting tremor, postural instability, and rigidity. These symptoms are due to the diminishing of dopamine in the nigrostriatal pathway and substantia nigra, which causes inhibition of the thalamus decreasing excitatory input to the motor cortex.1 Along with the key manifestations an individual with Parkinson’s Disease will experience problems associated with the disease or the antiparkinson medications. These co-occurring problems are hallucinations, dementia, daytime sleepiness, fatigue, depression, and pyschosis.2 Psychosis is a common problem in Parkinson’s Disease, and is characterized by paranoid delusions and hallucinations that are visual in nature.2 Risk factors for psychosis consists of advancing age, dementia, sleep disorders, and high doses of antiparkinson drugs.1

The explanation of the processes in the nervous system, which lead to the distressing results of a completely changed lifestyle as well as behavior, is important for understanding the origins of the disease. For all movements/actions the body performs, the brain gathers information about the body position which comes together in the striatum. The striatum, in cooperation with the substantia nigra and other parts of the brain, sends out commands for balance and coordination. The substantia nigra produces dopamine, the neurotransmitter which is crucial to human movement and controlling of balance. In Parkinson's disease, there is a dying off of the nerve cells producing dopamine in the substantia nigra, resulting in a large loss of dopamine in the brain, which causes a disbalance in the dopamine/acetylcholine cooperation. (6)The effects are a lack of coordination of movements, manifesting through tremor, stiff muscles, difficult moving.

Parkinson’s Disease is known as one of the most common progressive and chronic neurodegenerative disorders. It belongs to a group of conditions known as movement disorders. Parkinson disease is a component of hypokinetic disorder because it causes a decreased in bodily movement. It affects people who are usually over the age of 50. It can impair an individual motor as well as non-motor function. Some of the primary symptoms of Parkinson’s disease are characterized by tremors or trembling in hands, legs and arms. In early symptoms the tremor can be unilateral, appearing in one side of body but progression in the disease can cause it to spread to both sides; rigidity or a resistant to movement affects most people with Parkinson’s disease,

Parkinson’s disease is affected by the degeneration of dopaminergic neurons which is responsible to produce dopamine. Dopaminergic neurons have their cell bodies in substantia nigra pars compacta (SNpc) in basal ganglia (O’Sullivan and Schmitz, 2007). Basal ganglia are a collection of interconnected gray matter nuclear masses deep within the brain”. These gray matter masses are caudate, putamen, globus pallidus, subthalamic nucleus and the substantia nigra. Basal ganglia receive its input through striatum (O’Sullivan and Schmitz, 2007).

Parkinson’s Disease is a very common disorder these days. Over 10 million people live daily with Parkinson worldwide. Parkinson’s Disease was named after an English surgeon James Parkinson who wrote a detailed description essay called Shaking Palsy in 1817. The average age for Parkinson’s Disease is between 45 to 70 years old but you can also have juvenile or young onset as well. Most common symptoms of Parkinson are tremors, bradykinesia or akinesia, or rigidity or stiffness, and balance disorder. Parkinson’s Disease doesn’t have a cure and the cause is unknown it could be a number of things genetics, environmental triggers, age, or gender. Parkinson’s Disease happens because the dopaminergic neuron dies and

Parkinson 's disease is a chronic progressive movement disorder of the central nervous system. Early in the course of the disease, the most obvious symptoms are movement-related; these include shaking, rigidity, slowness of movement and difficulty with walking and Parkinson’s like gait (leaning forward, small fast pace steps, shuffling, etc.). Parkinson’s involves the malfunction and death of nerve cells in the brain, entitled neurons. Although damage can be spread about, it primarily affects neurons in an area of the brain called the substantia nigra. The substantia nigra controls voluntary movement, produces the neurotransmitter dopamine, and regulates mood. When taking an in-depth look into the changes a Parkinson’s patient goes through, we see symptoms clearly connecting to that of the substantia nigra malfunctioning. Parkinson’s disease is a chronic and progressive disorder of the brain primarily affecting the motor system, but also affecting thinking and emotion.

Parkinson’s disease is a disease with a wide variety of disabilities recognizable as changes in appearance, posture, walking, and balance. In 1817, the English physician James Parkinson described these symptoms in his patients and has had his name become synonymous with the disease. In 1893 the substantia nigra of the basal ganglia was identified as an area of disease for Parkinson’s. Examination with the naked eye reveals a lack of black pigment in this portion of the brainstem. Subsequent follow up with the microscope showed a deterioration of the nerve cells in this area. The circuitous relationship between the substantia nigra and the basal ganglia explains many of the symptoms of Parkinson’s disease. Today the

Parkinson disease (PD) is a progressive neurodegenerative disorder characterized mainly by physical and psychological disabilities. This disorder was named after James Parkinson, an English physician who first described it as shaking palsy in 1817 (Goetz, Factr, and Weiner, 2002). Jean- Martin Charcot, who was a French neurologist, then progressed and further refined the description of the disease and identified other clinical features of PD (Goetz, Factr, and Weiner, 2002). PD involves the loss of cells that produce the neurotransmitter dopamine in a part of the brain stem called the substansia nigra, which results in several signs and symptoms (Byrd, Marks, and Starr, 2000). It is manifested clinically by tremor,

The most common neurodegenerative movement disorder today is Parkinson Disease (Barth et al., 2011), with a prevalence which increases with age – from just 0.01% of the population aged 40 – 44 years and increasing to 1% at age 65, then up to 22% by age 85 and over. The total number of people with PD is expected to continue grow in the coming decades because of the aging society and a range of environmental factors.